Pharmaceuticals & Life Sciences

“The estimated cost for pivotal (phase 3) studies for new drugs approved by the FDA is over $41,000 per patient. As the cost per patient continues to rise, it is critical to enhance patient engagement at every stage of the clinical journey to improve the efficiency and effectiveness of patient recruitment and retention.”
– Paresh Shah, CEO of MindLeaf

Patient Engagement Administrative Challenges


  To overcome these and other barriers to clinical trial success requires deep domain expertise in administrative, compliance and support services. That’s where MindLeaf can help.